This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, and licensing and acquisition deals.
- The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.
- In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.
- The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.
- Therapies in early-to-mid-stage development for Zika virus focus on the immune system and viral antigens. Candidates comprise DNA vaccines such as NIH's Zika Virus Vaccine and GeneOne's GLS-5700; Moderna's mRNA vaccine; Themis Bioscience's recombinant viral vector vaccine; Imutex's AGS-v vaccine; Johnson & Johnson's Ad26.ZIKV.001 vaccine; and Takeda's TAK-426 vaccine.
- There were eight licensing and asset acquisition activities involving Zika virus drugs during 2013-17, all of which occurred in either 2016 or 2017. The exclusive 2017 agreement between Emergent BioSolutions and Valneva - worth $58.3m - for the global rights to Valneva's Zika vaccine technology and ZIKV-VLA1601, was the largest deal during the period.
- The clinical trials distribution across Phases I-IV indicates that the trials for Zika virus are only in the early phase of development. All industry-sponsored clinical trials are ongoing, with one trial each for Takeda and Themis Bioscience. Takeda and Themis Bioscience both have one trial in Phase I.
For more information about this report visit https://www.researchandmarkets.com/research/7s7855/2018_zika_virus?w=4